<PAGE> 1
SECURITIES & EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) December 20, 1994
MERCK & CO., Inc.
(Exact name of registrant as specified in its charter)
New Jersey
(State or other jurisdiction of incorporation)
1-3305 22-1109110
(Commission File Number) (IRS Employer Identification No.)
One Merck Drive, PO Box 100, Whitehouse Station, NJ 08889-0100
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code (908)423-1000
<PAGE> 2
Item 5. Other Events
Incorporated by reference is a press release issued by the Registrant
on December 20, 1994, attached as Exhibit 99, concerning the Registrant's
announcement of the signing of a definitive agreement for the sale of its Kelco
business to Monsanto Company.
Item 7. Financial Statements and Exhibits
(c) Exhibit
Exhibit 99 - Press release issued December 20, 1994.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this Report to be signed on its behalf by
the undersigned hereunto duly authorized.
MERCK & CO., Inc.
By: /s/ Nancy V. Van Allen
----------------------
Nancy V. Van Allen
Assistant Secretary
December 28, 1994
0209S
<PAGE> 3
EXHIBIT INDEX
<TABLE>
<CAPTION>
Exhibit
Number Description
- ------- -----------
<S> <C>
99 Press release issued December 20, 1994.
</TABLE>
<PAGE> 1
EXHIBIT 99
FOR IMMEDIATE RELEASE
PRESS CONTACTS: KIM BRADLEY GARY LACHOW
(908) 423-4374 (WORK) (908) 423-6022 (WORK)
(610) 454-0768 (HOME) (908) 782-1232 (HOME)
INVESTOR CONTACT: JIM HINRICHS
(908) 423-6883 (WORK)
MERCK TO SELL KELCO TO MONSANTO
Whitehouse Station, NJ, December 20, 1994 -- Merck & Co., Inc.,
announced today the signing of a definitive agreement for the sale of its Kelco
business to Monsanto Company for $1.075 billion. As announced on August 16,
Merck's decision to sell this business reflects the Company's intention to
focus its resources on its core human and animal health business.
In its August 16 announcement, Merck said it hoped to choose a buyer
whose strategic interest will be to focus on the continuing growth and success
of Kelco's business. Monsanto manufactures and markets agricultural, chemical,
pharmaceutical and food ingredient products.
Kelco is a world leader in the development, application and production
of alginates and biogums used in applications such as health-care, food
processing, oil exploration, paper and textiles and personal care. Kelco, with
1994 sales of approximately $300 million, is headquartered in San Diego,
California, and employs approximately 1,300 people.
Closing of the transaction is expected in the first quarter of 1995.
Merck & Co., Inc, is a worldwide research-intensive company that
discovers, develops, produces and markets human and animal health products and
services. Merck, which is headquartered in Whitehouse Station, NJ, has
manufacturing facilities in 15 countries and eight research centers around the
world. Merck will spend an estimated $1.3 billion on research and development
in 1994. Merck's Medco unit is the leading pharmacy benefits management
company.
# # #
